Skip to content

Ganglioside GM1 Serum/Plasma Concentration

Published: August 9, 2026Updated: August 16, 2026

This test measures the amount of GM1 ganglioside, a complex sugar-lipid molecule found in your blood. It may be used to assess certain inherited metabolic disorders or neurological conditions.

Quick summary

["GM1 ganglioside levels help diagnose rare genetic or neurological conditions."]

Medically reviewed by WellAlly Editorial TeamLast reviewed August 16, 2026Editorial policy

Key facts at a glance

LOINC
17288-2
Short code
GM1 Gangl Ab Ser Ql IF
Synonyms
GM1 Gangl Ab Ser Ql IF
Category
chemistry
Sample
serum
Container
Red-top tube (SST)
Units
N/A
Fasting
false
Population
adult
Sex
all
Age range
18–65 years
Method
if
Specimen volume
5 mL
Stability
Room temperature: 4h, Refrigerated: 24h, Frozen: 7d
Hemolysis max
500
Lipemia max
1000
Icterus max
500
TAT
4–24 hours
Order
routine

Why Might This Test Be Ordered?

Your healthcare provider may recommend this test if you have symptoms like developmental delays, movement disorders, or neurological issues that suggest a metabolic or genetic disorder affecting GM1 ganglioside metabolism. It could also be part of a broader evaluation for conditions like GM1 gangliosidosis, a rare lysosomal storage disorder.

What Does This Test Involve?

A blood sample is drawn from a vein in your arm. The blood is then processed to separate serum or plasma, where the GM1 ganglioside concentration is measured using a specialized laboratory technique, such as high-performance liquid chromatography (HPLC) or mass spectrometry.

What Do Results Mean?

Results may indicate abnormal levels of GM1 ganglioside, which can suggest underlying metabolic or genetic conditions. However, interpretation depends on clinical context, including your symptoms and family medical history. Your doctor will discuss findings with you.

What Are Common Causes of Abnormal Results?

Abnormally high or low GM1 ganglioside levels may be linked to inherited metabolic disorders (e.g., GM1 gangliosidosis) or other rare genetic conditions affecting lipid metabolism. These conditions can cause progressive neurological symptoms.

Clinical interpretation

How abnormal results are interpreted and what conditions they suggest.

Clinical Significance: Understanding Your Results

Short name

GM1 Ganglioside Level

Frequently asked questions

What Could This Test Be Used For?
This test is primarily used for diagnostic purposes in patients suspected of having GM1 gangliosidosis or other rare metabolic disorders affecting GM1 ganglioside metabolism. It helps confirm or rule out specific genetic conditions that may require specialized treatment or management.
How Often Is This Test Performed?
This test is not routinely performed for screening in the general population. It is typically ordered based on specific clinical suspicion, family history, or symptoms suggestive of a metabolic disorder.
What Should I Expect Before or After the Test?
Before the test: No special preparation is usually needed, but inform your doctor about any medications you’re taking. After the test: You may experience mild bruising or soreness at the injection site, but rest assured that blood samples are handled safely and securely.
  1. 1
  2. 2
  3. 3

Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 16, 2026. · Read our editorial policy